BC PharmaCare Drug Information

The drug below is being considered for coverage under the BC PharmaCare program. PharmaCare is a government-funded drug plan that helps B.C. residents with the cost of eligible prescription drugs and medical supplies. For more information about PharmaCare, visit the PharmaCare website.

PharmaCare reviews each drug for treating a specific illness or medical condition (also called an "indication"). If PharmaCare decides to cover a drug, that coverage applies only to the indication(s) specified. In some cases, PharmaCare covers a drug only for people who have not responded to other drugs that treat the same indication.

More information about the PharmaCare drug review process is provided on the last page of this document.

Drug information	
Generic name (scientific name)	**selumetinib**
Brand name	**Koselugo®**
Manufacturer	Alexion Pharma GmbH
Indication	For the treatment of adult patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).
Has the drug been reviewed by CDA-AMC, or will CDA-AMC be reviewing it? (See note below.)	Yes For more information about the CDA-AMC Reimbursement Review (CRR) of selumetinib (Koselugo®), Search the CDA-AMC Reports.
Public input start date	Wednesday, **May 27**, 2026
Public input closing date	Tuesday, **June 23**, 2026, **at 11:59 pm**
How is the drug taken?	Selumetinib is taken orally (through the mouth).
How often is the drug taken?	Selumetinib is taken twice a day (approximately every 12 hours).

Drug information	

General drug and/or drug study information	NF1 is a rare genetic disorder of the nervous system which causes tumours to grow on nerves. Common symptoms of NF1 can include abnormally-coloured patches of skin, freckling under the arms and around the groin, and benign tumours in the skin and nerves called neurofibromas. Selumetinib is used in patients who have tumours that grow along their nerves called plexiform neurofibromas (PNs) which cannot be surgically removed. Selumetinib is a type of medicine called a mitogen-activated protein kinase (MEK) inhibitor. It works by blocking certain proteins which are known to be involved in the growth of tumour cells. Selumetinib may reduce the size of PNs caused by NF1.
	Studies looked at the following:
	• Tumour size reduction, as measured by:
	  ○ Objective Response Rate (ORR)
	• Pain reduction, as measured by:
	  ○ Pain Intensity Scale for plexiform neurofibromas (PAINS-pNF) chronic target PN pain intensity score in the pain full analysis set (FAS)
	  ○ Proportion of participants with chronic target PN pain palliation in the pain FAS
	  ○ Pain Interference Index (PII)-pnF pain interference total scores in the FAS
	• Health-related quality of life, as measured by:
	  ○ Plexiform Neurofibroma Quality of Life scale (plexiQoL) total score in the FAS
	• Motor function, as measured by:
	  ○ Patient-Reported Outcomes Measurement Information System (PROMIS) physical function total score
	• Bad reactions
	• Serious bad reactions
	• Patients leaving the trial due to bad reactions
	• Bad reactions of special interest, including cardiac toxicity and ocular toxicity

Other considerations	None

Note:
CDA-AMC (Canada's Drug Agency-L'Agence des Médicaments du Canada) is a national organization that reviews drugs on behalf of Canadian public sector plans when drug manufacturers want those plans to

provide coverage for the drug. For detailed information about the PharmaCare drug review process, including the role of the CDA-AMC Reimbursement Review (CRR) in that process, visit How PharmaCare Decides Which Drugs to Cover.

Table of Comparators Used to Treat the Same Indication		
Generic Name (Brand Name) of Drug Comparator	**Dosage Form**	**PharmaCare Status (if and how the drug is already covered)**
selumetinib (Koselugo®)	Oral Capsule	Under Review for adults Limited Coverage Benefit for pediatrics

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent national organization called Canada's Drug Agency (CDA-AMC) provides evidence-based recommendations to public drug plans across Canada through its reimbursement review process.

As part of the CDA-AMC's Clinical Reimbursement Review process, the Canadian Drug Expert Committee (CDEC) makes reimbursement recommendations for non-oncology pharmaceuticals to the participating federal, provincial, and territorial publicly funded drug plans. In developing its recommendations, the CDEC considers:

- whether the drug is safe and effective
- what the drug costs and whether it is a good value to the citizens of B.C.
- ethical considerations related to covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a BC PharmaCare coverage decision by considering:

- existing BC PharmaCare policies, programs and resources
- the evidence-informed advice of the CDA-AMC
- the recommendations and reimbursement conditions of the CDEC
- if a Ministry Initiated review, the advice of an independent expert group called the Drug Benefit Council (DBC)
- BC-specific patient input collected through the Your Voice website
- drugs already covered by BC PharmaCare that treat similar medical conditions
- the overall cost of covering the drug

Visit BC PharmaCare and Drug reviews for more information.

This document provides information only.
It does not take the place of advice from a physician or other qualified health care provider.